Global Next-Generation GLP-1 Therapeutics Market
Description
MARKET OVERVIEW:
The global Next-Generation GLP-1 Therapeutics Market is projected to register a CAGR of 18.6% during the forecast period from 2026 to 2034. Increasing prevalence of obesity, type 2 diabetes, cardiometabolic diseases, and rapid clinical development of dual, triple, oral, and long-acting incretin-based therapies are the factors driving the market growth. The market is moving beyond first-generation GLP-1 receptor agonists into a broader therapeutic category focused on stronger weight loss, improved glucose control, better tolerability, less frequent dosing, oral convenience, and expanded benefits across cardiovascular, renal, liver, and metabolic disease pathways.
Next-generation GLP-1 medicines include enhanced incretin therapies, such as GLP-1 receptor agonists, dual GLP-1/GIP agonists, triple GLP-1/GIP/glucagon agonists, GLP-1/amylin combos, small-molecule oral GLP-1 therapies and long-acting injectable formulations. These medicines are changing the therapy landscape for obesity and diabetes since they target appetite management, insulin secretion, glucose metabolism, stomach emptying and energy balance. The business opportunity is growing fast as obesity is more and more being seen as a chronic metabolic disease and not a lifestyle issue.
One key factor affecting the industry is the transition from diabetes-centric prescribing to obesity-first and cardiometabolic risk management. Patients, physicians, payers and pharmaceutical firms are becoming aware that weight loss may help with a number of downstream illnesses such as hypertension, sleep apnea, heart failure risk, progression of chronic kidney disease and fatty liver disease. This is spurring companies to create larger lifecycle strategies for GLP-1-based medications, such as combination therapy and multi-indication development. Another major development is the race for distinct formulations. Injectable GLP-1 medicines have gained considerable clinical and commercial momentum, but adherence, access, manufacturing capacity, GI side effects and pricing remain key challenges. This has prompted a considerable desire for oral GLP-1 therapy, injections given monthly or less frequently, and multi-hormone medicines that can deliver better efficacy at reasonable tolerance levels. With competition ramping up, product differentiation will be based not just on weight loss outcomes, but also on dosing convenience, safety profile, durability of response, patient retention, reliability of supply and payer approval.
MARKET DYNAMICS:
Driver: Rising Global Obesity and Metabolic Disease Burden Is Creating Sustained Demand
The main factors driving the growth of the market are the increasing prevalence of obesity and associated metabolic disorders. Obesity is highly related with type 2 diabetes, cardiovascular disease, renal disease, sleep apnea, osteoarthritis and metabolic liver disease. The healthcare system is under pressure to cut long-term treatment expenses for certain chronic illnesses. GLP-1 based medicines are increasing importance since they not only combine weight reduction and metabolic regulation, but also are attractive to doctors and patients when clinically important outcomes are desired.
Another driver of demand is that many of the previous treatment options have had minimal success in the long term. Lifestyle therapies are necessary but difficult to maintain for many people. Bariatric surgery is quite effective yet it is invasive and only suitable for specific groups of patients. Next-generation GLP-1 therapies offer a pharmacologic alternative that can produce significant weight loss and glycemic improvement without surgery. This is broadening the addressable patient base across obesity clinics, endocrinology practices, primary care networks, cardiology groups and digital health platforms.
Restraint: High Cost, Side Effects, Supply Constraints, and Reimbursement Challenges
Despite strong clinical and commercial potential, market growth is restrained by high therapy costs, gastrointestinal adverse events, reimbursement restrictions, and manufacturing constraints. The high cost of GLP-1-based medicines and the long-term nature of treatment may raise issues about affordability for individuals, employers, insurers, and public healthcare systems. Payers are carefully considering cost-effectiveness, real-world adherence, cardiovascular benefit and long-term outcome data before broadening coverage, as obesity treatment may include chronic therapy. Another problem is tolerability. Retention of patients may be affected by nausea, vomiting, constipation, diarrhea, and termination of medication. Next-generation products should allow for improved efficacy and acceptable tolerability, especially as patients compare with other treatments and dose forms. Wider primary care populations may see delayed adoption if side effects are poorly managed.
Opportunity: Oral GLP-1, Multi-Agonist Drugs, and Expanded Indications Open Major Growth Pockets
The largest opportunity lies in differentiated next-generation products that improve convenience, efficacy, and therapeutic reach. Oral GLP-1 medicines are set to become a huge pocket of growth as many patients choose pills over injections. Oral candidates that can achieve effective weight reduction and glycemic control with acceptable tolerability could dramatically increase treatment acceptance in primary care and earlier-stage patient groups. Multi-agonist medicines also represent a high value prospect. Dual GLP-1/GIP, triple GLP-1/GIP/glucagon and GLP-1/amylin combinations are under development to provide deeper weight loss, superior metabolic outcomes and broader cardiometabolic advantages. These medicines may alter the treatment landscape by bridging the gap between medication and bariatric surgery level outcomes.
SEGMENT ANALYSIS:
Dual and Triple Agonists Are Emerging as the Most Attractive Drug Class Segment
By drug class, dual GLP-1/GIP agonists and triple GLP-1/GIP/glucagon agonists are projected to secure a substantial market share throughout the projection period. These medicines are meant to build on standard GLP-1 receptor agonists by targeting different metabolic pathways. Dual agonists reduce glucose and body weight by complementary incretin actions, whereas triple agonists further add glucagon activity to impact energy expenditure and fat metabolism. The segment is gaining traction on the back of increased efficacy expectations in obesity therapy. There are better options now, and patients and physicians are no longer satisfied with moderate weight loss. Multi-agonist treatments are being positioned as premium next generation medications that can offer greater and more enduring effects. This makes them particularly attractive for patients with extreme obesity, type 2 diabetes, cardiometabolic risk or obesity-related comorbidities.
Obesity & Weight Management Is Expected to Remain the Leading Indication
The Next-Generation GLP-1 Therapeutics Market is predicted to see a significant change due to the emerging trends in Next-Generation GLP-1 Therapeutics Market such as obesity & weight management to be the largest and fastest-growing segment by indication in the Next-Generation GLP-1 Therapeutics Market. Obesity affects a large proportion of the global patient population and is increasingly regarded as a treatable chronic disease. The clinical success in weight loss has generated a considerable demand from patients, clinicians, employers and digital health companies. This sector of obesity also presents opportunity for wider care models. GLP-1 medicines are increasingly being paired with nutrition support, behavioral coaching, remote monitoring, diagnostic testing and long-term maintenance programs. Commercial opportunities are thus created not only for pharmaceutical firms, but also for telehealth providers, specialized pharmacies, insurers and integrated care platforms.
REGIONAL ANALYSIS:
North America Leads the Market, While Asia-Pacific Is Set to Witness Significant Growth During the Forecast Period
The Next-Generation GLP-1 Therapeutics Market is likely to continue to be dominated by North America due to high obesity prevalence, high acceptance of diabetes therapy, improved reimbursement frameworks, high patient awareness and presence of key pharmaceutical developers. The US continues to be the key revenue driver, with significant commercial uptake of obesity and diabetes treatments, specialist prescription, direct-to-consumer awareness and employer interest in weight management solutions driving growth. The Asia-Pacific market is projected to develop at the highest CAGR during the forecast period owing to the increasing incidence of diabetes, increasing obesity rates, rising healthcare expenditure by the middle class, increasing diagnostic rates, and the improved access to sophisticated metabolic therapies. China, Japan, India, South Korea and Australia are likely to be key growth markets as diabetes prevention, obesity management and cardiometabolic risk reduction become an increasing focus for healthcare systems.
COMPETITIVE ANALYSIS:
The Next-Generation GLP-1 Therapeutics Market is highly competitive and innovation-led, with large pharmaceutical companies, biotechnology firms, and metabolic disease specialists competing across efficacy, tolerability, route of administration, dosing frequency, indication expansion, manufacturing scale, and payer access. Competition is shifting from single GLP-1 receptor agonists toward multi-agonist platforms, oral small molecules, amylin combinations, and long-acting formulations. Eli Lilly and Novo Nordisk currently hold strong leadership positions due to their established incretin franchises and advanced pipelines. However, companies such as Roche, Amgen, Viking Therapeutics, Pfizer, AstraZeneca, Zealand Pharma, Boehringer Ingelheim, and Structure Therapeutics are investing aggressively in differentiated candidates. The next phase of competition will be shaped by late-stage clinical readouts, comparative efficacy, tolerability, oral convenience, and manufacturing reliability. Top 10 companies include:
Eli Lilly and Company
Novo Nordisk A/S
Roche Holding AG
Amgen Inc.
Viking Therapeutics, Inc.
Pfizer Inc.
AstraZeneca plc
Zealand Pharma A/S
Boehringer Ingelheim International GmbH
Structure Therapeutics Inc.
RECENT DEVELOPMENTS:
May 2026: Eli Lilly reported pivotal Phase 3 results for retatrutide, its investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. In the TRIUMPH-1 trial, participants receiving 12 mg retatrutide achieved average weight loss of 28.3% over 80 weeks, supporting its positioning as a leading next-generation obesity therapy candidate.
January 2026: Roche announced positive Phase II results for CT-388, its once-weekly dual GLP-1/GIP receptor agonist for people living with obesity. The company stated that the findings support advancement into late-stage development and strengthen Roche’s position in the competitive obesity therapeutics market.
April 2025: Eli Lilly announced successful Phase 3 results for orforglipron, its once-daily oral small-molecule GLP-1 receptor agonist. The candidate lowered A1C by 1.3% to 1.6% across doses and reduced weight by 7.9% at the highest dose in a key secondary endpoint, supporting the commercial potential of oral GLP-1 therapy.
SCOPE OF THE REPORT:
By Drug Class
Gain complete market intelligence on the Next-Generation GLP-1 Therapeutics Market: This report provides a strategic view of market size, CAGR outlook, demand trends, revenue forecast, pipeline direction, regional growth, and commercial opportunities across advanced GLP-1, dual agonist, triple agonist, oral GLP-1, and combination metabolic therapies.
Identify high-growth therapeutic opportunities: The study helps pharmaceutical companies, biotech firms, investors, licensing teams, and healthcare strategists understand demand across obesity treatment, type 2 diabetes, cardiometabolic risk reduction, MASH/NASH, renal protection, and next-generation metabolic disease management.
Support pipeline, investment, and business development decisions: The report highlights where competition is moving across drug class, route of administration, and indication, helping stakeholders evaluate attractive growth pockets such as oral GLP-1 therapies, triple agonists, GLP-1/amylin combinations, and long-acting injectable formulations.
Understand competitive positioning and innovation direction: The report evaluates leading companies such as Eli Lilly, Novo Nordisk, Roche, Amgen, Viking Therapeutics, Pfizer, AstraZeneca, Zealand Pharma, Boehringer Ingelheim, and Structure Therapeutics, enabling stakeholders to benchmark pipelines, product strategies, and market positioning.
Make informed decisions with future-ready GLP-1 market insights: This report is designed for decision-makers seeking opportunities in obesity pharmacotherapy, incretin innovation, chronic metabolic disease care, oral peptide alternatives, multi-agonist therapies, manufacturing scale-up, and global GLP-1 market expansion through 2034.
The global Next-Generation GLP-1 Therapeutics Market is projected to register a CAGR of 18.6% during the forecast period from 2026 to 2034. Increasing prevalence of obesity, type 2 diabetes, cardiometabolic diseases, and rapid clinical development of dual, triple, oral, and long-acting incretin-based therapies are the factors driving the market growth. The market is moving beyond first-generation GLP-1 receptor agonists into a broader therapeutic category focused on stronger weight loss, improved glucose control, better tolerability, less frequent dosing, oral convenience, and expanded benefits across cardiovascular, renal, liver, and metabolic disease pathways.
Next-generation GLP-1 medicines include enhanced incretin therapies, such as GLP-1 receptor agonists, dual GLP-1/GIP agonists, triple GLP-1/GIP/glucagon agonists, GLP-1/amylin combos, small-molecule oral GLP-1 therapies and long-acting injectable formulations. These medicines are changing the therapy landscape for obesity and diabetes since they target appetite management, insulin secretion, glucose metabolism, stomach emptying and energy balance. The business opportunity is growing fast as obesity is more and more being seen as a chronic metabolic disease and not a lifestyle issue.
One key factor affecting the industry is the transition from diabetes-centric prescribing to obesity-first and cardiometabolic risk management. Patients, physicians, payers and pharmaceutical firms are becoming aware that weight loss may help with a number of downstream illnesses such as hypertension, sleep apnea, heart failure risk, progression of chronic kidney disease and fatty liver disease. This is spurring companies to create larger lifecycle strategies for GLP-1-based medications, such as combination therapy and multi-indication development. Another major development is the race for distinct formulations. Injectable GLP-1 medicines have gained considerable clinical and commercial momentum, but adherence, access, manufacturing capacity, GI side effects and pricing remain key challenges. This has prompted a considerable desire for oral GLP-1 therapy, injections given monthly or less frequently, and multi-hormone medicines that can deliver better efficacy at reasonable tolerance levels. With competition ramping up, product differentiation will be based not just on weight loss outcomes, but also on dosing convenience, safety profile, durability of response, patient retention, reliability of supply and payer approval.
MARKET DYNAMICS:
Driver: Rising Global Obesity and Metabolic Disease Burden Is Creating Sustained Demand
The main factors driving the growth of the market are the increasing prevalence of obesity and associated metabolic disorders. Obesity is highly related with type 2 diabetes, cardiovascular disease, renal disease, sleep apnea, osteoarthritis and metabolic liver disease. The healthcare system is under pressure to cut long-term treatment expenses for certain chronic illnesses. GLP-1 based medicines are increasing importance since they not only combine weight reduction and metabolic regulation, but also are attractive to doctors and patients when clinically important outcomes are desired.
Another driver of demand is that many of the previous treatment options have had minimal success in the long term. Lifestyle therapies are necessary but difficult to maintain for many people. Bariatric surgery is quite effective yet it is invasive and only suitable for specific groups of patients. Next-generation GLP-1 therapies offer a pharmacologic alternative that can produce significant weight loss and glycemic improvement without surgery. This is broadening the addressable patient base across obesity clinics, endocrinology practices, primary care networks, cardiology groups and digital health platforms.
Restraint: High Cost, Side Effects, Supply Constraints, and Reimbursement Challenges
Despite strong clinical and commercial potential, market growth is restrained by high therapy costs, gastrointestinal adverse events, reimbursement restrictions, and manufacturing constraints. The high cost of GLP-1-based medicines and the long-term nature of treatment may raise issues about affordability for individuals, employers, insurers, and public healthcare systems. Payers are carefully considering cost-effectiveness, real-world adherence, cardiovascular benefit and long-term outcome data before broadening coverage, as obesity treatment may include chronic therapy. Another problem is tolerability. Retention of patients may be affected by nausea, vomiting, constipation, diarrhea, and termination of medication. Next-generation products should allow for improved efficacy and acceptable tolerability, especially as patients compare with other treatments and dose forms. Wider primary care populations may see delayed adoption if side effects are poorly managed.
Opportunity: Oral GLP-1, Multi-Agonist Drugs, and Expanded Indications Open Major Growth Pockets
The largest opportunity lies in differentiated next-generation products that improve convenience, efficacy, and therapeutic reach. Oral GLP-1 medicines are set to become a huge pocket of growth as many patients choose pills over injections. Oral candidates that can achieve effective weight reduction and glycemic control with acceptable tolerability could dramatically increase treatment acceptance in primary care and earlier-stage patient groups. Multi-agonist medicines also represent a high value prospect. Dual GLP-1/GIP, triple GLP-1/GIP/glucagon and GLP-1/amylin combinations are under development to provide deeper weight loss, superior metabolic outcomes and broader cardiometabolic advantages. These medicines may alter the treatment landscape by bridging the gap between medication and bariatric surgery level outcomes.
SEGMENT ANALYSIS:
Dual and Triple Agonists Are Emerging as the Most Attractive Drug Class Segment
By drug class, dual GLP-1/GIP agonists and triple GLP-1/GIP/glucagon agonists are projected to secure a substantial market share throughout the projection period. These medicines are meant to build on standard GLP-1 receptor agonists by targeting different metabolic pathways. Dual agonists reduce glucose and body weight by complementary incretin actions, whereas triple agonists further add glucagon activity to impact energy expenditure and fat metabolism. The segment is gaining traction on the back of increased efficacy expectations in obesity therapy. There are better options now, and patients and physicians are no longer satisfied with moderate weight loss. Multi-agonist treatments are being positioned as premium next generation medications that can offer greater and more enduring effects. This makes them particularly attractive for patients with extreme obesity, type 2 diabetes, cardiometabolic risk or obesity-related comorbidities.
Obesity & Weight Management Is Expected to Remain the Leading Indication
The Next-Generation GLP-1 Therapeutics Market is predicted to see a significant change due to the emerging trends in Next-Generation GLP-1 Therapeutics Market such as obesity & weight management to be the largest and fastest-growing segment by indication in the Next-Generation GLP-1 Therapeutics Market. Obesity affects a large proportion of the global patient population and is increasingly regarded as a treatable chronic disease. The clinical success in weight loss has generated a considerable demand from patients, clinicians, employers and digital health companies. This sector of obesity also presents opportunity for wider care models. GLP-1 medicines are increasingly being paired with nutrition support, behavioral coaching, remote monitoring, diagnostic testing and long-term maintenance programs. Commercial opportunities are thus created not only for pharmaceutical firms, but also for telehealth providers, specialized pharmacies, insurers and integrated care platforms.
REGIONAL ANALYSIS:
North America Leads the Market, While Asia-Pacific Is Set to Witness Significant Growth During the Forecast Period
The Next-Generation GLP-1 Therapeutics Market is likely to continue to be dominated by North America due to high obesity prevalence, high acceptance of diabetes therapy, improved reimbursement frameworks, high patient awareness and presence of key pharmaceutical developers. The US continues to be the key revenue driver, with significant commercial uptake of obesity and diabetes treatments, specialist prescription, direct-to-consumer awareness and employer interest in weight management solutions driving growth. The Asia-Pacific market is projected to develop at the highest CAGR during the forecast period owing to the increasing incidence of diabetes, increasing obesity rates, rising healthcare expenditure by the middle class, increasing diagnostic rates, and the improved access to sophisticated metabolic therapies. China, Japan, India, South Korea and Australia are likely to be key growth markets as diabetes prevention, obesity management and cardiometabolic risk reduction become an increasing focus for healthcare systems.
COMPETITIVE ANALYSIS:
The Next-Generation GLP-1 Therapeutics Market is highly competitive and innovation-led, with large pharmaceutical companies, biotechnology firms, and metabolic disease specialists competing across efficacy, tolerability, route of administration, dosing frequency, indication expansion, manufacturing scale, and payer access. Competition is shifting from single GLP-1 receptor agonists toward multi-agonist platforms, oral small molecules, amylin combinations, and long-acting formulations. Eli Lilly and Novo Nordisk currently hold strong leadership positions due to their established incretin franchises and advanced pipelines. However, companies such as Roche, Amgen, Viking Therapeutics, Pfizer, AstraZeneca, Zealand Pharma, Boehringer Ingelheim, and Structure Therapeutics are investing aggressively in differentiated candidates. The next phase of competition will be shaped by late-stage clinical readouts, comparative efficacy, tolerability, oral convenience, and manufacturing reliability. Top 10 companies include:
Eli Lilly and Company
Novo Nordisk A/S
Roche Holding AG
Amgen Inc.
Viking Therapeutics, Inc.
Pfizer Inc.
AstraZeneca plc
Zealand Pharma A/S
Boehringer Ingelheim International GmbH
Structure Therapeutics Inc.
RECENT DEVELOPMENTS:
May 2026: Eli Lilly reported pivotal Phase 3 results for retatrutide, its investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. In the TRIUMPH-1 trial, participants receiving 12 mg retatrutide achieved average weight loss of 28.3% over 80 weeks, supporting its positioning as a leading next-generation obesity therapy candidate.
January 2026: Roche announced positive Phase II results for CT-388, its once-weekly dual GLP-1/GIP receptor agonist for people living with obesity. The company stated that the findings support advancement into late-stage development and strengthen Roche’s position in the competitive obesity therapeutics market.
April 2025: Eli Lilly announced successful Phase 3 results for orforglipron, its once-daily oral small-molecule GLP-1 receptor agonist. The candidate lowered A1C by 1.3% to 1.6% across doses and reduced weight by 7.9% at the highest dose in a key secondary endpoint, supporting the commercial potential of oral GLP-1 therapy.
SCOPE OF THE REPORT:
By Drug Class
- GLP-1 Receptor Agonists
- Dual GLP-1/GIP Agonists
- Triple GLP-1/GIP/Glucagon Agonists
- GLP-1/Amylin Combination Therapies
- Others
- Injectable Therapies
- Oral GLP-1 Therapies
- Long-Acting/Depot Formulations
- Combination Formulations
- Others
- Obesity & Weight Management
- Type 2 Diabetes
- MASH/NASH & Metabolic Liver Disease
- Cardiovascular & Renal Risk Reduction
- Others
- North America (United States & Canada)
- Europe (Germany, UK, France, Spain, Italy and Rest of Europe)
- Asia-Pacific (China, Japan, India, South Korea, Australia and Rest of Asia-Pacific)
- Latin America (Brazil, Mexico, Argentina and Rest of Latin America)
- Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa and Rest of Middle East and Africa)
Gain complete market intelligence on the Next-Generation GLP-1 Therapeutics Market: This report provides a strategic view of market size, CAGR outlook, demand trends, revenue forecast, pipeline direction, regional growth, and commercial opportunities across advanced GLP-1, dual agonist, triple agonist, oral GLP-1, and combination metabolic therapies.
Identify high-growth therapeutic opportunities: The study helps pharmaceutical companies, biotech firms, investors, licensing teams, and healthcare strategists understand demand across obesity treatment, type 2 diabetes, cardiometabolic risk reduction, MASH/NASH, renal protection, and next-generation metabolic disease management.
Support pipeline, investment, and business development decisions: The report highlights where competition is moving across drug class, route of administration, and indication, helping stakeholders evaluate attractive growth pockets such as oral GLP-1 therapies, triple agonists, GLP-1/amylin combinations, and long-acting injectable formulations.
Understand competitive positioning and innovation direction: The report evaluates leading companies such as Eli Lilly, Novo Nordisk, Roche, Amgen, Viking Therapeutics, Pfizer, AstraZeneca, Zealand Pharma, Boehringer Ingelheim, and Structure Therapeutics, enabling stakeholders to benchmark pipelines, product strategies, and market positioning.
Make informed decisions with future-ready GLP-1 market insights: This report is designed for decision-makers seeking opportunities in obesity pharmacotherapy, incretin innovation, chronic metabolic disease care, oral peptide alternatives, multi-agonist therapies, manufacturing scale-up, and global GLP-1 market expansion through 2034.
Table of Contents
184 Pages
- 1. Executive Summary
- 1.1. Global Next-Generation GLP-1 Therapeutics Market Outlook
- 1.1.1. Global Next-Generation GLP-1 Therapeutics Market - Regional Analysis
- 1.1.2. Global Next-Generation GLP-1 Therapeutics Market - Segment Analysis
- 1.1.3. Global Next-Generation GLP-1 Therapeutics Market - Competitive Snapshot
- 1.2. Technology Roadmap Analysis
- 1.3. Market Opportunity Assessment
- 1.4. Key Investment Pockets
- 1.5. Analyst Recommendation
- 2. Overview And Scope
- 2.1. Market Coverage
- 2.2. Market Definition
- 2.3. Market Segmentation
- 2.4. Report Assumptions
- 2.5. Currency and Forecasting Parameters
- 3. Global Next-Generation GLP-1 Therapeutics Market Overview, By Region: 2020 Vs 2025 Vs 2034
- 3.1. Global Next-Generation GLP-1 Therapeutics Market, By Region (2020 VS 2025 VS 2034)
- 3.2. North America Next-Generation GLP-1 Therapeutics Market, By Country (2020 VS 2025 VS 2034)
- 3.3. Europe Next-Generation GLP-1 Therapeutics Market, By Country (2020 VS 2025 VS 2034)
- 3.4. Asia-Pacific Next-Generation GLP-1 Therapeutics Market, By Country (2020 VS 2025 VS 2034)
- 3.5. Latin America Next-Generation GLP-1 Therapeutics Market, By Country (2020 VS 2025 VS 2034)
- 3.6. Middle East & Africa Next-Generation GLP-1 Therapeutics Market, By Country (2020 VS 2025 VS 2034)
- 4. Global Next-Generation GLP-1 Therapeutics Market Dynamics
- 4.1. Market Overview
- 4.1.1. Market Drivers
- 4.1.2. Market Restraints/Challenges Analysis
- 4.1.3. Market Opportunities
- 4.2. PESTLE Analysis
- 4.3. Value Chain Analysis/Supply Chain Analysis
- 4.4. Porter’s Five Forces Model
- 4.5. Regulatory Landscape
- 4.6. Pricing Model Analysis
- 4.7. Technology Trend Analysis
- 4.8. Impact of AI, Digital Health, and Personalized Medicine on Market Growth
- 4.9. ESG and Sustainability Impact Analysis
- 5. Global Next-Generation GLP-1 Therapeutics Market, By Drug Class
- 5.1. Introduction / Key Findings
- 5.2. Global Next-Generation GLP-1 Therapeutics Market By Drug Class (2020 - 2034) (USD Million)
- 5.3. Key Findings for Next-Generation GLP-1 Therapeutics Market - By Drug Class
- 5.3.1. GLP-1 Receptor Agonists
- 5.3.2. Dual GLP-1/GIP Agonists
- 5.3.3. Triple GLP-1/GIP/Glucagon Agonists
- 5.3.4. GLP-1/Amylin Combination Therapies
- 5.3.5. Others
- 6. Global Next-Generation GLP-1 Therapeutics Market, By Route of Administration
- 6.1. Overview
- 6.2. Global Next-Generation GLP-1 Therapeutics Market By Route of Administration (2020 - 2034) (USD Million)
- 6.3. Key Findings for Next-Generation GLP-1 Therapeutics Market - By Route of Administration
- 6.3.1. Injectable Therapies
- 6.3.2. Oral GLP-1 Therapies
- 6.3.3. Long-Acting/Depot Formulations
- 6.3.4. Combination Formulations
- 6.3.5. Others
- 7. Global Next-Generation GLP-1 Therapeutics Market, By Indication
- 7.1. Overview
- 7.2. Global Next-Generation GLP-1 Therapeutics Market By Indication (2020 - 2034) (USD Million)
- 7.3. Key Findings for Next-Generation GLP-1 Therapeutics Market - By Indication
- 7.3.1. Obesity & Weight Management
- 7.3.2. Type 2 Diabetes
- 7.3.3. MASH/NASH & Metabolic Liver Disease
- 7.3.4. Cardiovascular & Renal Risk Reduction
- 7.3.5. Others
- 8. Global Next-Generation GLP-1 Therapeutics Market, By Region
- 8.1. Overview
- 8.2. Global Next-Generation GLP-1 Therapeutics Market, By Region (2020 - 2034) (USD Million)
- 8.3. Key Findings For Next-Generation GLP-1 Therapeutics Market - By Region
- 8.4. Global Next-Generation GLP-1 Therapeutics Market, By Drug Class
- 8.5. Global Next-Generation GLP-1 Therapeutics Market, By Route of Administration
- 8.6. Global Next-Generation GLP-1 Therapeutics Market, By Indication
- 9. Global Next-Generation GLP-1 Therapeutics Market - North America
- 9.1. Overview
- 9.2. North America Next-Generation GLP-1 Therapeutics Market (2020 - 2034) (USD Million)
- 9.3. North America Next-Generation GLP-1 Therapeutics Market, By Drug Class
- 9.4. North America Next-Generation GLP-1 Therapeutics Market, By Route of Administration
- 9.5. North America Next-Generation GLP-1 Therapeutics Market, By Indication
- 9.6. North America Next-Generation GLP-1 Therapeutics Market by Country
- 9.6.1. United States
- 9.6.2. Canada
- 10. Global Next-Generation GLP-1 Therapeutics Market - Europe
- 10.1. Overview
- 10.2. Europe Next-Generation GLP-1 Therapeutics Market (2020 - 2034) (USD Million)
- 10.3. Europe Next-Generation GLP-1 Therapeutics Market, By Drug Class
- 10.4. Europe Next-Generation GLP-1 Therapeutics Market, By Route of Administration
- 10.5. Europe Next-Generation GLP-1 Therapeutics Market, By Indication
- 10.6. Europe Next-Generation GLP-1 Therapeutics Market by Country
- 10.6.1. Germany
- 10.6.2. UK
- 10.6.3. France
- 10.6.4. Spain
- 10.6.5. Italy
- 10.6.6. Rest of Europe
- 11. Global Next-Generation GLP-1 Therapeutics Market - Asia-Pacific
- 11.1. Overview
- 11.2. Asia-Pacific Next-Generation GLP-1 Therapeutics Market (2020 - 2034) (USD Million)
- 11.3. Asia-Pacific Next-Generation GLP-1 Therapeutics Market, By Drug Class
- 11.4. Asia-Pacific Next-Generation GLP-1 Therapeutics Market, By Route of Administration
- 11.5. Asia-Pacific Next-Generation GLP-1 Therapeutics Market, By Indication
- 11.6. Asia-Pacific Next-Generation GLP-1 Therapeutics Market by Country
- 11.6.1. China
- 11.6.2. Japan
- 11.6.3. India
- 11.6.4. South Korea
- 11.6.5. Australia
- 11.6.6. Rest of Asia-Pacific
- 12. Global Next-Generation GLP-1 Therapeutics Market - Latin America
- 12.1. Overview
- 12.2. Latin America Next-Generation GLP-1 Therapeutics Market (2020 - 2034) (USD Million)
- 12.3. Latin America Next-Generation GLP-1 Therapeutics Market, By Drug Class
- 12.4. Latin America Next-Generation GLP-1 Therapeutics Market, By Route of Administration
- 12.5. Latin America Next-Generation GLP-1 Therapeutics Market, By Indication
- 12.6. Latin America Next-Generation GLP-1 Therapeutics Market by Country
- 12.6.1. Brazil
- 12.6.2. Mexico
- 12.6.3. Argentina
- 12.6.4. Rest Of Latin America
- 13. Global Next-Generation GLP-1 Therapeutics Market - Middle East & Africa
- 13.1. Overview
- 13.2. Middle East & Africa Next-Generation GLP-1 Therapeutics Market Size (2020 - 2034) (USD Million)
- 13.3. Middle East & Africa Next-Generation GLP-1 Therapeutics Market, By Drug Class
- 13.4. Middle East & Africa Next-Generation GLP-1 Therapeutics Market, By Route of Administration
- 13.5. Middle East & Africa Next-Generation GLP-1 Therapeutics Market, By Indication
- 13.6. Middle East & Africa Next-Generation GLP-1 Therapeutics Market, By Country
- 13.6.1. Saudi Arabia
- 13.6.2. UAE
- 13.6.3. Israel
- 13.6.4. South Africa
- 13.6.5. Rest of Middle East & Africa
- 14. Global Next-Generation GLP-1 Therapeutics Market - Competitive Landscape
- 14.1. Key Competitive Analysis
- 14.2. Key Strategies Adopted by the Leading Players
- 14.3. Global Next-Generation GLP-1 Therapeutics Market Competitive Positioning
- 14.3.1. Important Performers
- 14.3.2. Emerging Innovators
- 14.3.3. Market Players with Moderate Innovation
- 14.4. Company Market Share Analysis
- 14.5. Product Benchmarking
- 14.6. Partnership, Merger and Acquisition Analysis
- 14.7. Recent Developments
- 15. Global Next-Generation GLP-1 Therapeutics Market - Company Profiles
- 15.1. Eli Lilly and Company
- 15.1.1. Corporate Summary
- 15.1.2. Corporate Financial Review
- 15.1.3. Product Portfolio
- 15.1.4. Key Development
- 15.2. Novo Nordisk A/S
- 15.3. Roche Holding AG
- 15.4. Amgen Inc.
- 15.5. Viking Therapeutics, Inc.
- 15.6. Pfizer Inc.
- 15.7. AstraZeneca plc
- 15.8. Zealand Pharma A/S
- 15.9. Boehringer Ingelheim International GmbH
- 15.10. Structure Therapeutics Inc.
- 16. Our Research Methodology
- 16.1. Our Research Practice
- 16.2. Data Source
- 16.2.1. Secondary Source
- 16.2.2. Primary Source
- 16.3. Data Assumption
- 16.4. Analytical Framework for Market Assessment and Forecasting
- 16.5. Our Research Process
- 16.6. Data Validation and Publishing
- 17. Appendix
- 17.1. Disclaimer
- 17.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
